Market Place
Sourcing Support
Rapid Initiation with Sublocade® for Opioid Use Disorder at CSAM
19 Nov 2024 //
PR NEWSWIRE
Top investor Oaktree calls for board shake-up at Indivior
11 Nov 2024 //
FIERCE PHARMA
Indivior Responds to Oaktree Capital Letter to Board
07 Nov 2024 //
PR NEWSWIRE
Indivior Data Shows SUBLOCADE® Supports Long-Term Recovery
30 Oct 2024 //
PR NEWSWIRE
Indivior Announces Q3 2024 Financial Results
24 Oct 2024 //
PR NEWSWIRE
Indivior`s opioid treatment sales slump prompts second profit warning
10 Oct 2024 //
REUTERS
Indivior Provide Q3 2024 Results And FY 2024 Guidance
10 Oct 2024 //
PR NEWSWIRE
Indivior`s Sublocade Receives FDA Priority Review For Injection Site
07 Oct 2024 //
PR NEWSWIRE
Indivior Updates on Aelis Farma`s Phase 2B Results for Cannabis Use Disorder
04 Sep 2024 //
PR NEWSWIRE
Addex and Indivior Select Clinical Candidates from GABAB Modulator Collaboration
27 Aug 2024 //
GLOBENEWSWIRE
Addex And Indivior Select Clinical Candidates From GABAB Modulator Research
27 Aug 2024 //
GLOBENEWSWIRE
Indivior Picks Up Addex`s Addiction Asset After Epilepsy Drug Flop
27 Aug 2024 //
FIERCE BIOTECH
Indivior Announces BARDA`s First Order Of OPVEE For Opioid Preparedness
26 Aug 2024 //
PR NEWSWIRE
Indivior Resolves More Opioid Litigation With $86M Multi-State Agreement
29 Jul 2024 //
FIERCE PHARMA
Indivior Announces New $100M Accelerated Share Repurchase Program
25 Jul 2024 //
PR NEWSWIRE
Indivior shares soar on $100 mln buyback, opioid addiction drug sales rise
25 Jul 2024 //
REUTERS
Indivior shares dive on profit warning, dropping of schizophrenia drug
10 Jul 2024 //
REUTERS
Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT
09 Jul 2024 //
PR NEWSWIRE
Indivior Doses First Subject With Opioid Use Disorder Drug INDV-2000
10 Jun 2024 //
PR NEWSWIRE
Indivior Analyst Event Nyc: Full Year 2024 Guidance Reconfirmed
23 May 2024 //
PR NEWSWIRE
Indivior Announces Q1 2024 Financial Results
25 Apr 2024 //
PR NEWSWIRE
Court Provides Approval of Settlement with Purchaser in Antitrust Litigation
29 Feb 2024 //
PR NEWSWIRE
Indivior Announces Q3 2023 Financial Results
09 Nov 2023 //
PR NEWSWIRE
Indivior to fork over $385M in Suboxone antitrust settlement
24 Oct 2023 //
FIERCE PHARMA
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals
11 Oct 2023 //
PR NEWSWIRE
Indivior Publishes Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses
26 Sep 2023 //
PR NEWSWIRE
Click, Indivior to make digital therapeutics for addiction
08 Sep 2023 //
FIERCE BIOTECH
Wexler Boley & Elgersma LLP, Miller Law LLC, Hilliard Shadowen LLP, Motley Rice
28 Aug 2023 //
PR NEWSWIRE
Indivior Reaches Agreement with End Payor Class to Resolve Litigation Claims
21 Aug 2023 //
PR NEWSWIRE
Indivior to pay $30 million to settle health plans` Suboxone claims
21 Aug 2023 //
REUTERS
Indivior Announces Q2/H1 2023 Financial Results
27 Jul 2023 //
PR NEWSWIRE
Indivior Announces Four Abstracts Accepted for Presentation at Meeting
14 Jun 2023 //
PR NEWSWIRE
Indivior to Commence Trading on Nasdaq
12 Jun 2023 //
PR NEWSWIRE
US drugmaker Indivior to pay $102.5 million to settle Suboxone monopoly claims
02 Jun 2023 //
REUTERS
Indivior Reaches Agreement with States` Attorneys General
02 Jun 2023 //
PR NEWSWIRE
Indivior To Participate In Upcoming Investor Conferences
25 May 2023 //
PR NEWSWIRE
Indivior Form 20-F Registration Statement for Additional US Listing Available
23 May 2023 //
PR NEWSWIRE
FDA approves another new type of opioid overdose antidote nasal spray
23 May 2023 //
ENDPTS
Indivior Announces U.S. FDA Approval of OPVEE Nasal Spray
22 May 2023 //
PR NEWSWIRE
Indivior Announces Q1 2023 Financial Results
27 Apr 2023 //
PR NEWSWIRE
Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.
02 Mar 2023 //
PR NEWSWIRE
FY 2022 Financial Results Announced
16 Feb 2023 //
PR NEWSWIRE
Opiant Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
07 Feb 2023 //
GLOBENEWSWIRE
Opiant Announces Expiration of Hart-Scott-Rodino Waiting Period
06 Feb 2023 //
GLOBENEWSWIRE
Opiant Pharma Announces FDA Acceptance and Priority Review of NDA for OPNT003
19 Jan 2023 //
GLOBENEWSWIRE
Opiant Pharma Announces Completion of Rolling NDA Submission for OPNT003
22 Nov 2022 //
GLOBENEWSWIRE
Indivior to acquire Opiant Pharmaceuticals for $145 million
15 Nov 2022 //
PHARMABIZ
Narcan developer to be acquired by Indivior
15 Nov 2022 //
BIOPHARMADIVE
Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Indivior Bets $145M on Opiant’s Opioid Overdose Recovery Candidate
14 Nov 2022 //
BIOSPACE
Indivior snaps up Narcan owner for $145M upfront
14 Nov 2022 //
ENDPTS
Indivior Announces Q3 2022 Financial Results
27 Oct 2022 //
PRNEWSWIRE
Opiant to Report Third Quarter 2022 Financial Results and Host Conference Call
27 Oct 2022 //
GLOBENEWSWIRE
Opiant Pharma completes enrollment in phase 2 trial of OPNT002
08 Oct 2022 //
PHARMABIZ
Opiant Announces Completion of Enrollment in Ph 2 Trial of OPNT002, Naltrexone
06 Oct 2022 //
GLOBENEWSWIRE
Indivior To Participate in Upcoming Investor Healthcare Events
07 Sep 2022 //
PRNEWSWIRE
Indivior Recognizes National Recovery Month
01 Sep 2022 //
PRNEWSWIRE
Indivior: Access to Medication for Opioid Use Disorder
25 Aug 2022 //
PRNEWSWIRE
Opiant Announces Notice of Allowance for U.S. Patent Covering OPNT004
22 Aug 2022 //
GLOBENEWSWIRE
